Genmab — Oktober 2016
-
En rapport omkring et CR i NK T-cell Lymphona, som Novos omtaler - denne patient ville have få dage at leve, da darzalex behandlingen påbegyndtes http://www.nejm.org/doi/suppl/10.1056/NEJMc1605684/suppl_file/nejmc1605684_appendix.pdf
-
Nu har vi set off label på Amyloidosis http://www.jwatch.org/na42154/2016/08/28/daratumumab-advanced-light-chain-amyloidosis og NK T-cell Lymhona, der giver bevis for, at der er et marked udenfor MM til Darzalex
-
Tak Solsen.
-
http://www.nejm.org/doi/full/10.1056/NEJMc1605684?query=TOC en lidt lettere læselig udgave af NK T-cell Lymphona artiklen
-
super link solsen
-
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind
Ja de får godt nok meget spalte plads Novo Nordisk i øjeblikket - Men snart er det Genmab tur